AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 42 min read$NBIX

Cooke Julie sold $661K of NBIX

Cooke Julie (Chief Human Resources Officer) sold 4,216 shares of NEUROCRINE BIOSCIENCES INC (NBIX) at $156.77 ($0.66M total) on 2026-06-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Cooke Julie
Published Jun 4, 2026, 10:02 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 4, 2026, 10:05 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$NBIX
Neutral
medium confidence
Mentioned
$NBIX
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NBIXNeutralLow
01

Why it matters

The disclosed sale provides a datapoint on insider activity, but the pre-arranged 10b5-1 structure typically limits interpretive value for near-term price direction.

02

Market read

Insider selling disclosure for NBIX; likely sentiment-neutral unless paired with other catalysts.

03

What to watch

Traders may over-weight insider selling; the key is whether there is concurrent news (trial/regulatory/earnings) that would change fundamentals.

Relevance 6/10Novelty 6/10Timing: Filed after-hours today; sale occurred 2026-06-02.

Background

The article is an SEC Form 4 insider transaction filing (officer/direct holding) for Neurocrine Biosciences.

Company-level read

Ticker impact

$NBIXNeutralMedium confidence
Context

Neurocrine Biosciences insider disclosure shows HR officer Julie Cooke sold 4,216 shares in an open-market transaction under a 10b5-1 plan.

Expected impact

Low near-term impact; any reaction likely fades unless accompanied by other company-specific news.

Evidence & confidence

Form 4 insider sales are common and the filing explicitly notes a pre-arranged 10b5-1 plan, reducing signal strength versus discretionary selling.

Market effects

Sector

Minimal; single-company insider sale without accompanying operational/regulatory/drug-trial updates.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is under a 10b5-1 plan, it may reflect routine liquidity rather than bearish expectations.

Key entities

  • issuer
    Neurocrine Biosciences, Inc.

    NBIX insider transaction: HR officer Julie Cooke sold 4,216 shares at $156.7660 on 2026-06-02.

  • insider
    Julie Cooke

    Chief Human Resources Officer; sold shares directly under a Rule 10b5-1 plan.

Read at source← All news

Related articles

AUG 1
$NBIXMed

Neurocrine Biosciences, Inc. Q2 2026 Earnings Call Summary

Neurocrine Biosciences reported Q2 2026 results and discussed its shift to a diversified portfolio. Management said INGREZZA record new patient additions supported raised full-year guidance midpoint for 13% YoY growth. CRENESSITY launch progress and Soleno and VYKAT XR acquisitions were highlighted. Soleno was $2.9B cash-funded; quarter-end cash was $500M and no debt.

yahoo.com7 min
JUL 31
$NBIXMedAI 8/10

Neurocrine (NBIX) Q2 2026 Earnings Call Transcript

Thursday, July 30, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Vice President of Investor Relations - Todd Tushla Chief Executive Officer - Kyle W. Gano Chief Financial Officer - Matthew Abernethy Chief Commercial Officer - Eric S. Benevich Chief Medical Officer - Sanjay Keswani Chief Business Officer - Samir Siddhanti Need a quote from a Motley Fool analyst?

fool.com7 min
JUL 30
$NBIXHigh

NEUROCRINE BIOSCIENCES INC (NBIX): Results of Operations and Financial Condition

NEUROCRINE BIOSCIENCES INC (NBIX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 q2-2026xearningsrelease.htm EX-99.1 Document Exhibit 99.1 Neurocrine Biosciences Reports Second-Quarter 2026 Financial Results Total Second-Quarter 2026 Revenue Grew 39% Year-Over-Year to $959 Million INGREZZA ® (valbenazine) 2026 Net Sales Guidance Raised to $2.825 to

SEC EDGAR 8-K6 min
JUL 9
$CRNXHighAI 9/10

Why Crinetics Stock Soared 99% This Week

Vertex (VRTX) agreed to acquire Crinetics (CRNX) for about $10B, or $85.00 per share in all cash, approved by both boards and expected to close in Q3 2026. CRNX shares rose about 99% to ~$83.54. Vertex projects the endocrine franchise could exceed $5B peak annual sales. Peers NBIX and CORT also gained on M&A expectations.

yahoo.com7 min
JUL 1
$NBIXMed

Neurocrine Biosciences Initiates Phase 2 Study of Crinecerfont in Pediatric Patients Under 4 Years Old with Classic Congenital Adrenal Hyperplasia

Neurocrine Biosciences (Nasdaq: NBIX) began a Phase 2 open-label, single-arm study of crinecerfont (CRENESSITY) in 20 children aged 3 months to under 4 years with classic congenital adrenal hyperplasia. The 24-week trial targets safety/tolerability and will assess PK/PD biomarkers, aiming to support a supplemental NDA to expand the U.S. indication. Enrollment also reached target in a EU Phase 2 study for birth to under 2 years.

prnewswire.com4 min